AUG 31, 2017 07:00 AM PDT

Characterization of H4-IC31 candidate: particles and composition

Speakers
  • Associate Scientist at SGS Canada and Sanofi Pasteur Ltd., Toronto, ON
    Biography
      Sasmit Deshmukh is an Associate Scientist at SGS Canada and Sanofi Pasteur Ltd., Toronto, ON. He received his PhD in Chemistry at Concordia University, Montreal, QC. He has over 10 years of extensive multidisciplinary research experience in chemistry, biochemistry and biophysics.
    • Head of Biophysics and Conformation Unit, Biochemistry Platform, Analytical R&D North America, Sanofi Pasteur Ltd
      Biography
        Marina Kirkitadze is Head of Biophysics and Conformation Unit, Biochemistry Platform, Analytical R&D North America, Sanofi Pasteur Ltd. She has 15 years' experience in the vaccine industry. Marina received her PhD in Biological Sciences at the Institute of Protein Research, Russian Academy of Sciences, Pushchino, Russia, and her MBA from the University of Phoenix, AZ, USA.

      Abstract:

      DATE: August 31, 2017
      TIME: 7:00am PT, 10:00am ET, 4:00pm CET

      A tuberculosis (TB) vaccine consisting of a recombinant fusion protein (referred to as H4) combined with a novel synthetic cationic adjuvant, IC31®, is in development. The H4 fusion protein consists of two immunogenic mycobacterial antigens, Ag85B and TB10.4. The IC31® adjuvant is a mixture of KLK, a leucine-rich peptide (KLKL5KLK), and the oligodeoxynucleotide ODN1a, a TLR9 ligand.  This webinar will discuss Phase Analysis Light Scattering (PALS) and Raman spectroscopy methods to characterize the H4-IC31 vaccine formulation. The PALS method can be used to assess vaccine product quality and consistency in terms of particle size, zeta potential and conductivity. These parameters can differentiate between the IC31® adjuvant and the H4-IC31 vaccine candidate; hence, the method can serve as a control during vaccine formulation. Additionally, Electrical Sensing Zone (ESZ) was used as an orthogonal method to measure size of IC31 and H4-IC31 particles. Furthermore structural changes of H4 protein upon adjuvantation were characterized by Raman, FTIR and CD spectroscopy. The applicability of these biophysical methods to characterize vaccine components in the final H4-IC31 drug product without desorption will be discussed. 


      Show Resources
      You May Also Like
      JUN 05, 2018 06:30 AM PDT
      C.E. CREDITS
      JUN 05, 2018 06:30 AM PDT
      DATE: June 5, 2018TIME: 06:30AM PDT, 3:30PM CEST Viscous liquids are a challenge in every lab that deals with them. Depending on how viscous a liquid is, pipetting is either...
      MAY 03, 2018 11:00 AM PDT
      MAY 03, 2018 11:00 AM PDT
      DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
      MAY 22, 2018 08:00 AM PDT
      C.E. CREDITS
      MAY 22, 2018 08:00 AM PDT
      DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
      JUN 26, 2018 06:00 AM PDT
      C.E. CREDITS
      JUN 26, 2018 06:00 AM PDT
      Date: June 26, 2018Time: 6:00 a.m. PDT, 9:00 a.m. EDT, 1500 CEST Today’s hematology analyzers employ various methods for enumerating platelets. These methods include: e...
      SEP 12, 2017 08:00 AM PDT
      SEP 12, 2017 08:00 AM PDT
      DATE: September 12, 2017TIME: 8:00am PT, 11:00am ETEvery year, millions of dollars are wasted on poorly characterized and performing antibodies.  Key researchers in the antibody co...
      DEC 11, 2018 10:00 AM PST
      C.E. CREDITS
      DEC 11, 2018 10:00 AM PST
      DATE: December 11, 2018TIME: 11:00 PSTThis webinar will focus on how Reichert's Surface Plasmon Resonance (SPR) systems can generate additional valuable information that is not...
      Loading Comments...